Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
Vinod Pullarkat, Keith W. Pratz, Hartmut Döhner, Christian Récher, Michael J. Thirman, Courtney D. DiNardo, Pierre Fenaux, Andre C. Schuh, Andrew H. Wei, Arnaud Pigneux, Jun‐Ho Jang, Gunnar Juliusson, Yasushi Miyazaki, Dominik Selleslag, Martha Arellano, Chenglong Liu, Jean Ridgeway, Jalaja Potluri, Jovita Schuler, Marina Konopleva
Abstract
Secondary acute myeloid leukemia (sAML), a subset of AML, may arise from antecedent hematologic disorders (antecedent myelodysplastic syndrome or chronic myelomonocytic leukemia [A-MDS/CMML]) or complication of prior cytotoxic chemotherapy or radiation therapy (therapy-related AML [tAML]) [ 1 ]. It comprises about 25% to 35% of AML cases, occurring more frequently with age [ 2 ]. Rising incidence of sAML is potentially related to increased survival from prior malignancies, greater use of chemotherapy, and improved reporting of myeloid malignancies [ 2 ]. sAML is frequently associated with adverse genetics, including TP53 mutations, which are associated with poor outcomes in myeloid malignancies [ 2 , 3 ]. Compared with primary AML, sAML is associated with unfavorable outcomes regardless of age, posing unique clinical challenges [ 4 , 5 ].